Meenakshi Hegde

Jan 6, 2025 | digitalcommons.library.tmc.edu | Meenakshi Hegde |Shoba Navai |Christopher DeRenzo |Sujith K. Joseph

Keywords Humans, Sarcoma, Middle Aged, Female, Male, Receptor, ErbB-2, Adult, Immunotherapy, Adoptive, Aged, Receptors, Chimeric Antigen, T-Lymphocytes, Lymphocyte Depletion, Prospective Studies, Vidarabine, Cyclophosphamide, Treatment Outcome Abstract In this prospective, interventional phase I study (NCT00902044) for patients with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T-cells (HER2-CART) after lymphodepletion with cyclophosphamide (Cy) +/−...

Apr 24, 2024 | nature.com | Meenakshi Hegde |Shoba Navai |Khaled Sanber |Ahmed Gad |Riyue Bao |Ahmed Salem | +5 more

AbstractIn this prospective, interventional phase 1 study for individuals with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) after lymphodepletion with fludarabine (Flu) ± cyclophosphamide (Cy): 1 × 108 T cells per m2 after Flu (cohort A) or Flu/Cy (cohort B) and 1 × 108 CAR+ T cells per m2 after Flu/Cy (cohort C). The primary outcome was assessment of safety of one dose of HER2 CAR T cells after lymphodepletion.